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Abstract During the use of glucocorticoids (GCs), both
vertebral and nonvertebral fracture risk are increased, due
to the direct and indirect negative effects of GCs on bone,
muscles, and the activity of the underlying inflammatory
diseases. Inhibition of bone formation and increased
apoptosis of osteocytes play a consistent and crucial role in
the pathogenesis of glucocorticoid-induced osteoporosis
(GIO), while changes in bone resorption during GC-use are
variable. To prevent fractures, important general measures
include using the lowest possible dose of GCs, treating the
underlying disease adequately, a healthy life style, ade-
quate calcium and vitamin D supplementation, and regular
exercise. Although it has been shown that bisphosphonates
reduce vertebral fractures during the first 2 years of GC-
treatment, there are no data on long-term use of bisphos-
phonates during GC-treatment. Of some concern in GIO,
bisphosphonates reduce bone turnover, including bone
formation, which is already downregulated by GCs. In
contrast, the use of the anabolic agent teriparatide is more
effective in reducing vertebral fractures than alendronate.
In summary, bisphosphonates remain the first choice in the
first two years of treatment in GC-treated patients with high
fracture risk, but their long-term effects on bone quality
and fracture risk reduction remain uncertain.
Keywords Glucocorticoids  Osteoporosis 
Bisphosphonates  Fracture 
Bone mineral density  Bone quality
Pathogenesis of glucocorticoid-induced
osteoporosis (GIO)
In healthy women bone formation and bone resorption are
usually coupled, and both upregulated in postmenopausal
osteoporotic women. However, these processes are
uncoupled during glucocorticoid (GC)-treatment [1–4]. It
has been consistently shown that bone formation is inhib-
ited during the use of GCs. Indeed, the major inhibiting
direct effect of GCs on bone is on osteoblast proliferation
and function. This is mediated by GC-induced reduction of
osteoblast-relevant growth factors such as insulin-like
growth factor (IGF)-1 and 2, and transforming growth
factor b1 (TGF b1). GCs stimulate the apoptosis of
osteoblasts, interfere with the Wnt-signaling pathway, at
least partly by upregulation of Dkk-1, and can stimulate the
differentiation of mesenchymal stem-cells into the adipo-
cyte pathway, at the expense of differentiation into osteo-
blasts [1–4].
Data on bone resorption are less consistent in GC-users,
since bone resorption may be increased or unchanged. One
of the reasons for that variation might be the effect of the
underlying disease. For example, bone resorption can be
upregulated due to cytokines such as TNFa and IL-6 in
systemic inflammatory diseases such as rheumatoid
arthritis (RA). Therefore, in a study of healthy, young,
male volunteers, low-dose prednisone (10 mg per day for
1 week) was associated with a decrease of 22 % of serum
osteocalcin, a marker of bone formation, while no changes
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were found in pyridinoline and deoxypyridinoline, markers
of bone resorption [5].
GCs also stimulate the apoptosis of osteocytes, the
orchestrators of bone turnover. Earlier studies have shown
that the use of GCs reduces the intestinal absorption of
calcium and augments the urinary excretion of calcium,
which may result in a tendency to secondary hyper-
parathyroidism, and elevated bone resorption [1–4].
Finally, the use of GCs may lead to muscular weakness
and, theoretically, an increased risk of falling.
Thus, the pathogenesis of GIO is multifactorial, with a
leading role for inhibited bone formation. The use of GCs
may lead to a reduction in bone mineral density (BMD),
and (thus) to an increased fracture risk. It is important to
note that the fracture threshold in GC-users is different than
in GC-users, probably due to a negative effect on bone
quality, which cannot be detected by dual energy X-ray
absorptiometry (DXA)-measurements. Specifically, at the
same level of BMD or T-score, the fracture risk is higher in
GC-users than in non GC-users [6].
(Nonpharmacological) prevention of fractures
during the use of GCs
Since the pathogenesis of GIO is multifactorial, several
therapeutic options should be considered for fracture pre-
vention in GC-users. First, GCs should be used in the
lowest possible dosage and for as short a duration as pos-
sible [7]. For example, in a chronic systemic inflammatory
diseases such as polymyalgia rheumatica (PMR), it has
been suggested that combining GCs with methotrexate
(MTX), another powerful immunosuppressant might be
‘‘steroid-sparing’’ [8].
In addition, adequate supplementation of calcium and
vitamin D are important, particularly in GC-users because
of the effects of GCs on calcium metabolism and muscular
weakness. A healthy life style that includes regular weight-
bearing exercise, smoking cessation, and limited alcohol
intake will also benefit bone health [1–4]. Calcium and
vitamin D alone may partially preserve bone mass at tra-
becular sites in the ‘‘control’’ arm of some of the bispho-
sphonate studies, particularly during long-term GC-
treatment [9]. However, for most GC-users, calcium and
vitamin D are necessary but not sufficient.
The negative effects of the underlying disease for which
the GCs are prescribed, are also important on bone health.
For instance, in an observational study in early rheumatoid
arthritis (RA) patients in 1994, before the introduction of
biologics and combinations of conventional disease modi-
fying antirheumatic drug (DMARD) therapy, a consider-
able amount of bone loss was observed after 2 years:
-2.4 % at the spine and -4.3 % at the hips [10]. However,
in a subgroup analysis of this study, bone loss in both the
spine and hips after 1 year was much greater in those
patients with high CRP-levels ([20 mg/dL) than in those
with low CRP-levels (\20 mg/dl): -2.1 and -0.2 %,
respectively. A similar trend was seen at the lumbar spine
for patients with low functional capacity (HAQ-score[-1)
compared to patients with a better HAQ-score (\-1). In
line with that observation, it has been demonstrated that
with the use of MTX and the tumor necrosis factor alpha
(TNFa)-blocking agent infliximab, the usually occurring
bone loss at the spine and hips could be arrested, both at
1 year and after 3 years [11, 12]. The same bone-preserv-
ing effect was also found for adalimumab [13] and for the
IL-6 blocker tocilizumab [14], illustrating that the negative
effect of the underlying RA can be effectively counteracted
with potent biological DMARDs.
The effects of GCs and bone in rheumatoid
arthritis (RA)
One of the most intriguing questions within the field of
rheumatology is the effect of the use of GCs in patients
with RA on bone. There has been a preferential focus on
RA, because the studies on the effects of GCs on bone are
larger and the studies are of generally higher quality in
RA, compared to other inflammatory rheumatic diseases.
As described, both the use of GCs and active RA can have
a devastating effect on bone, but it is well-known that
GCs have strong anti-inflammatory effects. In other
words, is it possible to counteract the negative effects on
bone by adequate suppression of systemic inflammation
with GCs?
This question has been investigated in the BeSt study, a
novel study comparing four different treatment strategies in
which treatment adjustments were made continuously
when low disease activity, defined as disease activity score
(DAS) B2.4, was not reached in patients with recent-onset
RA [15]. The treatment strategies were group 1, sequential
monotherapy starting with methotrexate (MTX); group 2,
step-up combination therapy starting also with MTX; group
3, initial combination therapy with MTX, sulphasalazine
and quickly tapered high dose of prednisone (more or less
the same as the conventional COBRA-scheme); and group
4, initial combination therapy with MTX and the TNFa
inhibitor infliximab. After 2 years of DAS-guided treat-to-
target therapy, BMD decreased at the hips by -1.1 %
(group 1), -0.2 % (group 2), -0.2 % (group 3), and
-0.6 % (group 4). At the lumbar spine, the bone loss was
-0.4, -1.6, -0.5, and -1.0 %, respectively [16]. It was
concluded from BeST that generalized bone loss was
modest in all 4 groups of patients and, that the generalized
bone loss was not greater in patients initially treated with
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high-dose prednisone. In addition, radiological joint dam-
age was low in all 4 groups. This suggests that the negative
effect of GCs on bone in early RA might be partially
outweighed by the strong anti-inflammatory effects of GCs
on bone [17, 18].
The BeSt study was among the first modern treat-to-
target studies that showed that the use of GCs may not be
as harmful to the bone in early RA, as previously sus-
pected. It is important to note that the BEST study was a
DAS-guided treat-to-target study, in which several prede-
fined treatment options were prescribed to patients who did
not have low disease activity. Namely, it was not a ran-
domized controlled trial comparing the effects of pred-
nisone versus placebo. However, it has recently been
demonstrated that prednisone 10 mg per day versus pla-
cebo in early RA-patients treated with MTX, had a positive
effect not only on disease activity, but also on radiological
joint damage [19]. Additionally, generalized bone loss both
at the spine and hips could be prevented in these patients,
regardless of whether GCs were used, with calcium, vita-
min D, or bisphosphonates [20].
While not all studies have reached these same conclu-
sions and clinical trials are too short and have too few
subjects to examine fracture endpoints effectively, these
data suggest that optimal treatment of the underlying dis-
ease using a treat-to-target strategy may prevent bone loss
in RA, and probably also in other systemic inflammatory
diseases.
Pharmacological prevention of fractures
with bisphosphonates during the short-term use
of GCs
Bisphosphonates are effective, generally safe, inexpensive,
and are the most widely-used drugs for the prevention of
fractures in postmenopausal women with high fracture risk.
Reduction of vertebral- and nonvertebral-, including hip,
fractures has been shown for alendronate and later for
risedronate and zoledronic acid in randomized controlled
trials with 3–5 years of observation [12, 21–23]. Based on
this substantial database in the postmenopausal population,
the specific evidence for bisphosphonates in GC-users is
much smaller.
In a meta-analysis, a comparison was made between
fracture data in postmenopausal women and in GC-users:
the vertebral fracture rate was comparable, relative risk
0.58 (postmenopausal women) versus 0.48 (GC-users),
with a larger standard deviation in GC-users indicating a
smaller number of patients studied [24]. In line with this
finding, the reduction in nonvertebral fracture reduction
was comparable in magnitude (relative risk 0.81), but not
statistically significant for GC-users, attributable to the
very small number of nonvertebral fractures in the GIO
literature.
Thus, there are strong clinical trial and epidemiological
data to support the prescription of bisphosphonates in the
first 2 years of GC-treatment. The prescription of bispho-
sphonates in the early phase of GC-treatment is particularly
attractive, since in the early phase the dosage of GC is
usually high, and the underlying disease is very active.
Using the Clinical Practice Research Datalink (CPRD) of
the United Kingdom, Van Staa et al. found that immedi-
ately after starting GCs, fracture risk was increased, inde-
pendent of changes in BMD, likely related to inflammatory
disease activity, elevated fall risk, and the direct toxic
effect of GC on osteoblasts and osteocytes [25].
However, in routine clinical practice, the use of bis-
phosphonates in GC-users is suboptimal. Multiple studies
have been shown that internationally, less than 50 % of
chronic GC-users are prescribed bisphosphonates or other
GIO prevention therapies [26, 27]. Slight differences in
guidelines from different major groups (ACR, NOF, IOF)
concerning the thresholds (i.e., which T-score?, which GC
dosage?) above which bisphosphonates should be initiated
has further confounded this issue [2]. In a recent study in
695 GC-treated individuals, not treated with bisphospho-
nates for at least 6 months, patients were randomized to
intervention by a pharmacist or placebo. The authors found a
statistically significant increase in bisphosphonate users, but
the difference between the groups was small: 11 % (after
intervention) versus 9 % [28]. Thus, it remains a challenge
even in high-risk GC-treated patients, particularly early in
GC-use, to assure that bisphosphonates are prescribed.
Pharmacological prevention of fractures
with bisphosphonates during the long-term use
of GCs
Unfortunately, GCs are often prescribed for several years
or more in many patients with systemic inflammatory
rheumatic diseases (and other inflammatory diseases), but
there is a paucity of outcome data to inform prevention
efforts. Extrapolation of the data from postmenopausal
women may be hazardous, because of the difference in the
pathogenesis of loss of bone strength in postmenopausal
women compared to GC-treated patients. In post-
menopausal women, bone resorption and bone formation
are both usually upregulated, and bisphosphonates are
therefore very attractive since they lower bone turnover.
However, in GC-users the critical issue is the reduced bone
formation, since in bisphosphonate users bone resorption is
decreased and bone formation is secondarily decreased.
Thus, the use of bisphosphonates during long-term GC-use
might lead to very low bone formation activity [29], which,
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at least theoretically, might lead to more brittle bones with
severely deteriorated bone micro-architecture and low bone
strength, and a high susceptibility for fractures, including
atypical femoral fractures [30]. Indeed among the case
reports of atypical fractures, a number of the patients have
been concurrently using GCs [31–33].
What type of data would be needed to fill this evidence
gap? A large long-term placebo-controlled study
(3–5 years) in GC-users at high risk for fractures would
theoretically be the best way to observe differences in
typical fracture rates and unusual events (such as atypical
fractures) in bisphosphonate users versus placebo, but it is
currently unethical to use long-term placebo in high-risk
GC-patients. Furthermore, this study would require thou-
sands of patients followed for upwards of 10 years to fully
answer this important question. Thus, a fracture trial to
solve this dilemma is untenable and infeasible. When
changes in BMD are used as the primary endpoint, fewer
patients are needed, but the problem remains the same;
namely, GC-treated patients with high fracture risk are only
offered placebo. In addition changes in BMD as primary
endpoint are difficult to interpret, since GCs might have a
more deleterious effect on bone quality than on BMD,
resulting in a different fracture threshold. In other words,
suppose the BMD response is better during the use of
bisphosphonates than for placebo in GC-users, this does
not necessarily mean that the increase in bone strength
parallels the increase in BMD. Another option could be
animal studies, but although long-term animal studies
might provide some insight in changes in BMD or some
aspects of bone quality in animals, these data probably
would not necessarily reflect fracture data or bone quality
changes in humans.
In summary, we agree that bisphosphonates should be
used in the first 2 years of GC-treatment, particularly in
those at high fracture risk. However, for long-term use of
GCs, insufficient data exist for the use of bisphosphonates.
In addition, there are both theoretical and at least anecdotal
concerns about long-term bisphosphonate use in GC-users,
because both GCs and long-term bisphosphonate use may
inhibit bone formation.
Pharmacological prevention of fractures
with drugs other than bisphosphonates
during the use of GCs
It has been shown in an RCT in 114 patients that 1 year
treatment with raloxifene has a positive effect on the BMD
of the lumbar spine and total hip, but not on the femoral
neck [34]. In addition, markers of bone formation and bone
resorption were decreased, as expected, since raloxifene is
an antiresorptive drug.
Theoretically, strontium ranelate is an attractive option,
since it has a stimulating effect on bone formation and a
negative effect on bone resorption [35]. However, these
effects seem to be small, and strontium ranelate has, to our
knowledge, not been systematically investigated in GC-
treated patients. Of relevance, a recent major limitation is
that strontium should not be prescribed in patients with an
elevated cardiovascular risk (which is quite common in
many GC-users). Denosumab, a monoclonal antibody
against RANKL, might be an attractive new therapeutic
agent for GC-treated patients. In a 12-month placebo-
controlled trial in patients with rheumatoid arthritis con-
currently receiving treatment with GCs or bisphosphonates,
denosumab therapy increased BMD and reduced bone
turnover (determined by measurement of levels of serum
type I C-telopeptide and serum procollagen 1 N-terminal
peptide) compared with placebo [36]. However, since
denosumab strongly reduces bone turnover, it may have the
same potential disadvantages as bisphosphonates for long-
term use of treatment during the use of GC. On the other
hand, denosumab has a stronger effect on bone turnover
than bisphosphonates and it requires carefully testing in
GIO, with patients followed long term to fully understand
its comparative efficacy and ultimately its safety in this
setting. A large clinical trial is underway that will provide
efficacy data on denosumab in GIO.
In an RCT in 428 GC-treated patients, it was demon-
strated that the use of teriparatide was more effective than
the active comparator alendronate. Teriparatide resulted in
a greater increase in the BMD of the lumbar spine and of
the hips (both total hip and femoral neck) and it reduced
(morphometric) vertebral fractures: 1.7 versus 7.7 %
(p = 0,007). There was no reduction in nonvertebral
fracture rate, probably related to limited power [37]. As
expected, a significant increase in osteocalcin and P1NP
(both markers of bone formation) were seen, and an
increase in serum CTX as well. This study has significantly
enriched the literature for several reasons:
– a reduction in vertebral fractures was found;
– the study was performed not with placebo, but with
alendronate as an active comparator; and
– the study duration of 3 years is longer than in
comparable studies in GC-treated patients.
More recently, the effect of teriparatide was also studied
in 92 GC-treated men. The investigators found a larger
increase in the BMD of the lumbar spine and of the hips in
the teriparatide group than in the risedronate-treated male
patients [38]. None of the patients on teriparatide but 5
(10.6 %) on risedronate developed a new clinical fracture
(p = 0.056). Interestingly, the effects on bone quality were
also investigated by high-resolution QCT at the 12th tho-
racic vertebra and by finite element analysis. With
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HRQCT, larger improvements were found for integral and
trabecular BMD; with finite element analysis an increased
vertebral strength was found for axial compression, ante-
rior bending, and axial torsion. In the same patients, it was
also determined that increases in serum P1NP after 3 and
6 months correlates with improvement in the above-men-
tioned measurements of biomechanical properties in the
teriparatide-treated patients, but not in the risedronate
group [39]. This again illustrates not only the bone for-
mation stimulating effect of teriparatide, which is impor-
tant in GC-users, but also that measurement of P1NP at
baseline and after 3–6 months might be a useful marker in
GC-treated patients in which teriparatide is prescribed.
In many countries, the prescription of teriparatide is
limited by the high medication costs and it is often a second-
line drug for osteoporotic patients who refracture during
treatment with bisphosphonates. Beyond the cost and
inconvenience of a daily injection, there is also the issue of a
short duration of use of teriparatide (a 2 years course of
therapy at best). The issue then arises of what to do after a
course of teriparatide for a patient who still remains on GCs?
In postmenopausal women, treatment with teriparatide is
usually followed by rapid bone loss, which can be prevented
by administering a subsequent antiresorptive agent. There-
fore, we suggest that in GC-users as well, teriparatide should
be followed by a bisphosphonate or another antiresorptive
agent (e.g., denosumab, raloxifene). However, in these
patients, monitoring is difficult. Changes in BMD after
sequential therapy with bisphosphonates, followed by teri-
paratide and then an antiresorptive drug are very difficult to
interpret, how to extrapolate these BMD-changes to changes
in bone strength? The predictive value of fractures by the use
of newer techniques such as peripheral Quantitative CT or
finite element analysis has not yet been conclusively
demonstrated in GC-using patients. Although these tech-
niquesmay providemore insight into the pathophysiology of
changes in metabolic bone diseases, such as GIO, the addi-
tional value for the individual patients remains to be
demonstrated.
At present, the best way to monitor during sequential
therapy is to attend to the well-known general measures
including the use of the lowest possible dose of GC, adequate
control of the disease activity of the underlying disease, fall-
prevention, and supplementation of calcium and vitamin D.
Considerations around future anti-osteoporosis
drugs in GIO
Odanacatib
Cathepsin K is a protease that primarily induces the
degradation of bone matrix by osteoclasts [40]. For
odanacatib, a selective cathepsin K-inhibitor, reliable data
are available from phase II-studies, and the phase III-study
has not yet been published. In a randomized controlled
(phase 2) trial in 339 patients, odanacatib 50 mg once
weekly was compared with placebo. There was a greater
increase in the BMD of both the lumbar spine and the total
hip was observed: 5.5 versus -0.2 and 3.2 versus -0.9 %,
respectively [41]. During treatment with odanacatib, a very
exciting phenomenon was observed; namely, while bone
resorption and bone formation are usually coupled, there
seems, after roughly 1 year, to be some uncoupling in
odanacatib-treated patients. Serum CTX decreased during
long-term treatment with odanacatib, as with antiresorptive
drugs, but markers of bone formation only initially
decrease but then gradually return to baseline (after
1 year). The uncoupling of the second year of treatment,
with no inhibiting effect on bone formation, makes oda-
nacatib a potentially very attractive drug for GC-treated
patients. A clinical trial is needed to address this question.
Monoclonal antibodies against sclerostin
Sclerosteosis and Van Buchem disease are two closely
related rare disorders resulting in endosteal hyperostosis,
which are characterized by progressive generalized
osteosclerosis, particularly in the mandible and skull,
sometimes complicated by entrapment of cranial nerves
[42]. In healthy adults, sclerostin is expressed by osteo-
cytes, but not in patients with sclerosteosis and van
Buchem disease. Sclerostin has an inhibiting effect on bone
formation by antagonizing the Wnt-signaling pathway,
which plays an important role in bone formation [42].
Theoretically, it would be very attractive to block scle-
rostin, e.g., by monoclonal antibodies in GIO. Recently, it
has been shown in a study in postmenopausal women that
romosozumab leads to a greater increase in BMD of the
spine and hips than the active comparator teriparatide, with
a very large (but transient) increase in makers of bone
formation [43]. These data are promising, and particularly
because of the very strong bone formation stimulating
effect, monoclonal antibodies could prove to be very
helpful in patients with GIO, although the optimal scheme
and dosage (and safety profile) must be further
investigated.
Conclusions
Patients using GCs are at high risk for fractures, due to the
direct and indirect negative effects of Gcs on bone, mus-
cular weakness, and activity of the underlying inflamma-
tory disease. To prevent fractures, general measures are
important, including using the lowest possible dose of GCs
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and treating the underlying disease adequately, and a
healthy life style including adequate calcium and vitamin D
supplementation, and regular weight-bearing exercise.
In the initial phase of GC-treatment, the dosage of GC is
often high, and the underlying inflammatory disease is com-
monly very active. Therefore, anti-osteoporotic drugs are
often indicated in these patients. In terms of bisphosphonates,
an increase in BMD and reduction in vertebral fractures has
been documented in studies up to 24-months.
In contrast, in the chronic use of GC, the dosage of GC
is usually lower, and the underlying inflammatory disease
under better control. However, since GC-use is dominated
by its inhibiting effect on bone formation, and bisphos-
phonates inhibit bone turnover, this combination could lead
to depressed bone formation. It can be speculated that this
could increase the risk of atypical femur fractures.
Based on the pathophysiology, teriparatide, an
osteoanabolic agent, is a more attractive option in longer
term GC-users since it induces a larger increase in BMD
and a stronger reduction in vertebral fracture rate than the
active comparator alendronate. Limitations of teriparatide
include a high medication cost and a short duration of use.
Denosumab has not yet been tested in GIO and where it
might fit into the treatment algorithm, remains still uncer-
tain. Theoretically, the development of new drugs, odana-
catib and monoclonal antibodies against sclerostin, with an
uncoupling of bone formation and bone resorption in favor
of bone formation, is an attractive future options for the
prevention of fractures in GC-treated patients. However,
randomized clinical trials are needed to affirm or refute any
preliminary enthusiasm.
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